Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Phase 2a, Open Label, Multi Center, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases
Rochester, Minn.
The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory (SLE) with nephritis (Subprotocol B) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C).
-
Biorepository: RA patients in sustained remission (RAsM)
Rochester, Minn.
The purpose of this study is to create a biorepository of biosamples from patients with rheumatoid arthritis (RA) in sustained remission. Identifying biomarkers associated with failure vs success of immunosuppressive treatments (DMARD) tapering is a critical need which will allow to maximize the benefits and safety of available treatments.
-
Mayo Clinic Rheumatoid arthritis cohort (MaCRO) biorepository (MaCRO)
Rochester, Minn.
The purpose of this study is to create a biobank with a linked database including medical data and biospecimens from adult (>18 years) patients with rheumatoid arthritis (RA) and individuals with positive cyclic citrullinated peptide antibodies (anti-CCPantibodies) who do not yet meet classification criteria for RA (i.e. pre-RA), as well as comparators without RA. We propose to recruit and enroll 1,500 participants with RA and pre-RA and 1500 participants without RA.
-
Spondyloarthritis Research Program: Biorepository of biosamples from patients with psoriatic arthritis
Rochester, Minn.
The purpose of this study is to create a biorepository of biosamples from patients with psoriatic arthritis (PsA). This biorepository will enable future investigation of biomarkers associated with PsA.
Closed for Enrollment
-
Pharmacogenomics-driven Individualized Prediction of Treatment Response to Anti-rheumatic Medications in Patients with Rheumatoid Arthritis
Rochester, Minn.
Study objective: Define pharmacogenomics markers and clinical phenotype features associated with response to RA treatments. Using electronical medical records data and a blood draw with DNA for genotyping from prospectively recruited patients seen in rheumatology clinic (n=100), we will identify genomic markers and leading phenotype features of responders to routinely used anti-rheumatic medications at 3 and 6 months of treatment based on disease activity score with 28-joint count (DAS28), accounting for socioeconomic factors, comorbidities, RA characteristics and prior anti-rheumatic medication use. We hypothesize that: Patients responding to antirheumatic medication(s) and their combinations share similar phenotype and/or genomic markers.
.